ArticlePCN reports : psychiatry and clinical neurosciences2026
Nationwide expansion of the EGUIDE project in Japan: A nine-year overview.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to describe the nationwide reach, longitudinal growth, and geographic dissemination of the Effectiveness of Guideline for Dissemination and Education in Psychiatric Treatment (EGUIDE) project in Japan from 2016 to 2024. Methods: The EGUIDE project is a nationwide, multicenter implementation initiative designed to promote the dissemination of clinical practice guidelines, specifically the Guidelines for Pharmacological Treatment of Schizophrenia and the Treatment Guidelines II: Major Depressive Disorder. The project provides educational lectures primarily for psychiatrists and other mental health professionals. We descriptively summarized the cumulative numbers of lectures delivered, participants enrolled, and participating institutions from 2016 to 2024. In addition, we calculated the proportion of hospitals with psychiatric departments that participated in each prefecture. Results: Between 2016 and 2024, a total of 194 guideline lectures on schizophrenia and major depressive disorder were conducted. The cumulative number of participants reached 4785 across 763 institutions, of which 592 were hospitals with psychiatric departments, corresponding to approximately 20% of all such hospitals nationwide. Participating hospitals were distributed across most prefectures in Japan, indicating broad geographic coverage. Conclusion: Over the 9-year period, the EGUIDE project continuously delivered guideline lectures and steadily expanded its participant and institutional base. The nationwide distribution of participating institutions suggests that the project has established a broad implementation platform for psychiatric guideline dissemination in Japan. Continued efforts may further strengthen this dissemination network and support future evaluations of its impact on psychiatric practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.